Drug Profile
Research programme: protein kinase inhibitors - Johnson & Johnson/Teva Pharmaceutical Industries
Latest Information Update: 24 Oct 2021
Price :
$50
*
At a glance
- Originator Cephalon; Johnson & Johnson Pharmaceutical Research & Development
- Developer Cephalon; Johnson & Johnson Pharmaceutical Research & Development LLC
- Class
- Mechanism of Action Protein kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Cancer; CNS disorders
Most Recent Events
- 25 Sep 2006 Discontinued - Preclinical for Cancer in USA (unspecified route)
- 25 Sep 2006 Discontinued - Preclinical for CNS disorders in USA (unspecified route)
- 16 Jan 2001 New profile